However, measuring exosomal PD-L1 to define which cancer patients may benefit from checkpoint blockade, as well as after treatment, to assess therapeutic efficacy is an attractive complementary diagnostic assay that can aid in the risk-benefit analysis. Here, CD274 is linked to cancer.